Reports of a potential merger between AstraZeneca and Bristol Myers Squibb, which would create a pharmaceutical giant valued at nearly $400 billion, have been met with widespread skepticism and bewilderment from analysts and investors. AstraZeneca's shares fell by as much as 6% to 11,872p on Monday following the news, marking its steepest decline. Analysts from Jefferies described the reported talks as "more than a 'head scratcher'" and noted that AstraZeneca, with its strong growth and innovation profile, has little need for such a "financial engineering" deal. UBS, which rates AstraZeneca as a 'buy', was also surprised, raising concerns that large pharmaceutical mergers often damage research productivity.
Several key concerns were highlighted regarding the proposed merger. Timing was a central objection, as Bristol Myers Squibb's portfolio faces approximately $30 billion in exclusivity losses before AstraZeneca's own patent cliff, which is expected after 2030. Analysts also pointed to significant business overlap, particularly in non-small cell lung cancer, where Bristol Myers Squibb's Opdivo ($10.05 billion in 2025 sales) directly competes with AstraZeneca's Imfinzi ($6.06 billion in 2025 sales). This overlap, along with other competitive areas, would likely invite intense scrutiny from antitrust regulators in both the U.S. and Europe, with BMO Capital Markets suggesting such a deal is "less likely to materialize" due to potential anti-competitive issues.
Furthermore, the financial and strategic rationale for AstraZeneca was questioned. While a deal could expand AstraZeneca's U.S. footprint and potentially offer cost synergies, many analysts and investors, including portfolio managers from Union Investment and ATG Healthcare, argued it would disrupt a well-run company with a strong pipeline and dilute its growth outlook. BMO Capital Markets also indicated that neither company has the financial capacity to buy the other outright, with Bristol Myers Squibb's market cap at $133.41 billion and AstraZeneca's at $195.93 billion, suggesting that a deal would likely involve a large quantity of premium equity, which analysts found drastic given Bristol Myers Squibb's low earnings multiple. The consensus among AstraZeneca shareholders was that Bristol Myers Squibb shareholders would be the primary beneficiaries of any combination.
